Marex Group’s Autolus Therapeutics AUTL Stock Holding History

Marex Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.6K	Sell	17,857 -525,000	-97%	-$824K	﹤0.01%	1096
2026 Q1	$749K	Buy	+542,857	New	+$825K	﹤0.01%	513
2025 Q3	–	Sell	-12,500	Closed	-$28.5K	–	858
2025 Q2	$28.5K	Hold	12,500	–	–	﹤0.01%	614
2025 Q1	$19.4K	Hold	12,500	–	–	﹤0.01%	666
2024 Q4	$29.4K	Sell	12,500 -3,000	-19%	-$10.1K	﹤0.01%	652
2024 Q3	$56.3K	Buy	15,500 +3,000	+24%	+$12K	﹤0.01%	559
2024 Q2	$43.5K	Hold	12,500	–	–	﹤0.01%	594
2024 Q1	$79.8K	Buy	+12,500	New	+$78K	﹤0.01%	434

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marex Group's AUTL Position: Q2 2026 in Review

Marex Group reduced its Autolus Therapeutics (AUTL) stake by 97% in Q2 2026, selling an estimated $824K and leaving 17,857 shares worth $28.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Marex Group first reported a position in AUTL in Q1 2024 and has held it in 8 quarters since. The position peaked at $749K in Q1 2026. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Marex Group held 17,857 shares of Autolus Therapeutics worth $28.6K as of Q2 2026.
Marex Group sold 525,000 Autolus Therapeutics shares in Q2 2026, an estimated $824K.
Autolus Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1096 holding.
Marex Group first reported a position in Autolus Therapeutics in Q1 2024 and has held it in 8 quarters since.
Marex Group's Autolus Therapeutics position peaked at $749K in Q1 2026.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.